Jubilant Pharmova Net Profit Down by 79%

Noida, July 29, 2025: Jubilant Pharmova Ltd (NSE: JUBLPHARMA) has reported 79% year-on-year decline in consolidated net profit, which fell to ₹1,025 million (Rs 102.5 crore) for the first quarter of financial year 2026 (Q1FY26). This  profit reduction occurred despite a nearly 10% year-on-year rise in revenue from operations, reaching ₹19,007 million (Rs 1,900 crore). The company attributed the decline in profit to higher finance costs and a normalisation effect, following an exceptional gain recorded in the previous year.

In a key strategic move, the company also confirmed the approval of the slump sale of its Active Pharmaceutical Ingredients (API) business to its wholly-owned subsidiary, Jubilant Biosys Ltd. This transfer is anticipated to conclude on 1st September 2025.

The stock closed the day, today, down by 1.75%.

Consolidated Financial Performance (₹ in million)

Jubilant Pharmova’s consolidated financial performance for Q1FY26, compared to previous periods, is detailed as follows:

• Revenue from Operations stood at ₹19,007 million in Q1FY26, representing a +9.8% YoY increase from ₹17,317 million in Q1FY25, but a -1.5% QoQ decline from ₹19,288 million in Q4FY25.
• Total Income reached ₹19,127 million in Q1FY26, showing a +9.6% YoY growth from ₹17,457 million in Q1FY25, and a -1.4% QoQ decrease from ₹19,407 million in Q4FY25.
• Profit Before Tax (PBT) was ₹1,544 million in Q1FY26, a sharp -69.1% YoY drop from ₹4,997 million in Q1FY25, and a -25.0% QoQ decline from ₹2,060 million in Q4FY25.
• Net Profit for Q1FY26 was ₹1,025 million, a significant -78.7% YoY decrease from ₹4,818 million in Q1FY25, and a -32.2% QoQ fall from ₹1,513 million in Q4FY25.
• Earnings Per Share (EPS) mirrored the net profit trend, standing at ₹6.49 in Q1FY26, down -78.7% YoY from ₹30.44 in Q1FY25, and -33.2% QoQ from ₹9.71 in Q4FY25.

Segment-Wise EBIT Contribution

Analysing the segment-wise contribution to Earnings Before Interest and Tax (EBIT) for Q1FY26 (in ₹ million):

• Radiopharma reported revenue of ₹8,686 million and EBIT of ₹986 million.
• Allergy Immunotherapy had revenue of ₹1,914 million and EBIT of ₹613 million.
• Sterile Injectables (CDMO) generated revenue of ₹3,926 million and EBIT of ₹431 million.
• CRDMO recorded revenue of ₹3,114 million and EBIT of ₹270 million.
• Generics posted revenue of ₹1,660 million but an EBIT of (₹4) million, indicating it was a drag on margins.
• Proprietary Novel Drugs had no revenue contribution but recorded an EBIT of (₹62) million.

Radiopharma and Allergy units continued to be the top contributors to EBIT, while the Generics segment remained challenged.

Standalone Results and API Business Sale

Jubilant Pharmova’s standalone net profit for Q1FY26 stood at ₹58 million, a notable improvement compared to a loss of ₹102 million in Q1FY25. However, this figure represents a sharp drop from ₹136 million in Q4FY25, primarily due to the reclassification of the API segment as “discontinued operations” following its approved slump sale.

Standalone performance details (₹ in million):

• Revenue from Continuing Operations was ₹595 million in Q1FY26, a slight decrease from ₹607 million in Q4FY25, but an increase from ₹532 million in Q1FY25.
• Profit from Discontinued Operations was ₹26 million in Q1FY26, a significant drop from ₹169 million in Q4FY25, but an improvement from a loss of ₹161 million in Q1FY25.
• Net Profit (Total) stood at ₹58 million in Q1FY26, compared to ₹136 million in Q4FY25 and a loss of ₹102 million in Q1FY25.

Corporate Action: API Business Slump Sale

The company’s board had approved the transfer of its Active Pharmaceutical Ingredients (API) business via slump sale to Jubilant Biosys Limited, a wholly-owned subsidiary, on 12th June 2025. This strategic move was subsequently ratified by shareholders on 24th July 2025. The transaction is set to close on 1st September 2025, with the settlement primarily through the issuance of shares.

The company stated that “Following this transaction, the company’s continuing standalone operations will be limited to management and support services.”

Management Insight

Arjun Shanker Bhartia, Joint Managing Director, emphasised the company’s refined focus: “The API business divestiture enables sharper execution across Radiopharma, Allergy, and Sterile CDMO. Our growth momentum in high-value services continues.”

Insights For Investors: What Now?

Jubilant Pharmova’s Q1FY26 results present a mixed picture for investors. While the company achieved nearly 10% revenue growth, the significant 79% decline in net profit due to higher finance costs and the normalisation effect from a prior-year exceptional gain is a key concern. The market’s immediate reaction, with shares falling by over 2%, reflects this profitability pressure.

However, a critical strategic development is the approved slump sale of the API business. Management’s view is that this divestiture will enable “sharper execution” and a stronger focus on higher-value segments such as Radiopharma, Allergy Immunotherapy, and Sterile Injectables (CDMO), where the company has shown stronger EBIT contributions. The reclassification of the API segment as discontinued operations in standalone results highlights this shift.

For investors, the near-term volatility might persist due to the profit decline. However, the long-term outlook will depend on the successful execution of the strategy to streamline operations and enhance profitability in its core, differentiated portfolio. The company’s substantial consolidated asset base and equity reserves provide a foundation for this strategic realignment.

What’s Ahead For The Company?

Jubilant Pharmova is entering a transition phase marked by restructuring and a renewed focus on high-margin businesses. Here’s what investors can expect going forward:

• Sharper Strategic Focus: With the API business now divested, the company is concentrating on higher-value verticals like Radiopharma, Allergy Immunotherapy, and Sterile Injectables, which have consistently contributed positively to EBIT.
• Margin Improvement Potential: Exiting the low-margin Generics and API businesses could lead to improved overall margins, especially as Radiopharma and Allergy units scale up further.
• Streamlined Operations: The simplification of the business structure is expected to improve execution, reduce costs, and enhance operating efficiency across remaining verticals.
• Near-Term Pressure Remains: Despite the strategic reset, the sharp YoY decline in net profit and rising finance costs may weigh on sentiment and performance in the near term.
• Execution-Driven Growth Outlook: Going forward, the success of Jubilant Pharmova will largely depend on how effectively it capitalises on its focused portfolio, manages capital allocation, and scales differentiated capabilities across its core segments.

Strategic Outlook

Despite facing near-term profit pressure, Jubilant Pharmova remains committed to its differentiated portfolio, particularly in high-value segments like Radiopharma and CRDMO. With a consolidated asset base exceeding ₹130,000 million and equity reserves of ₹62,391 million, the company maintains solid fundamentals that are expected to support long-term value creation.

About the Company

Jubilant Pharmova Limited (NSE: JUBLPHARMA) is a globally integrated pharmaceutical company. It operates across various key segments, including Radiopharmaceuticals, Allergy Therapy, Contract Development and Manufacturing Organisation (CDMO), Contract Research and Development Manufacturing Organisation (CRDMO), and Generics. The company is listed on both the National Stock Exchange (NSE) and the BSE, and is a part of the esteemed Jubilant Bhartia Group.

REF:  https://nsearchives.nseindia.com/corporate/JUBLPHARMA_29072025134350_Results_final_signed.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations